AGC Bi­o­log­ics to build new gov­ern­ment-fund­ed $350M Japan­ese fa­cil­i­ty

CD­MO AGC Bi­o­log­ics is con­struct­ing a new gov­ern­ment-fund­ed ¥50 bil­lion ($350.5 mil­lion) fa­cil­i­ty at its Yoko­hama Tech­ni­cal Cen­ter in Japan, which is rough­ly half an hour’s dri­ve from West Tokyo.

The new build, an­tic­i­pat­ed to be op­er­a­tional in 2026, will of­fer ser­vices in pre­clin­i­cal and com­mer­cial man­u­fac­tur­ing for mam­malian-based pro­tein bi­o­log­ics, as well as cell ther­a­pies and mR­NA. Ac­cord­ing to the Seat­tle, WA-head­quar­tered man­u­fac­tur­er, this will be one of Japan’s largest mam­malian-based fa­cil­i­ties, hous­ing 2,000L sin­gle-use biore­ac­tors and 4,000L or larg­er re­ac­tors for mam­malian cell cul­ture pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER